Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK H7N9 Influenza Vaccines in Adults
NCT02177734Phase 1Withdrawn
- Sponsor
- GSK
- Start
- Mar 2016
- Primary completion
- Jun 2016
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, single-blind trial of GSK3277510A and GSK-3277509A (6 arms), sponsored by GSK. Primary endpoints: Humoral immune response in terms of vaccine-homologous hemagglutination inhibition (HI) antibody titers at Day 42, Occurrence of each solicited local symptom and 4 more. Planned start Mar 2016; status: withdrawn.
02
Drugs
GSK3277510AGSK-3277509A
Beyond the preview
Go deeper on NCT02177734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02177734.